A rare loss-of-function variant p.Arg138* in SLC30A8 encoding the zinc transporter 8 (ZnT8) 70 enriched in Western Finland protects against type 2 diabetes (T2D). We recruited relatives of the 71 identified carriers and showed that protection was associated with better insulin secretion due to 72 enhanced glucose responsiveness and proinsulin conversion, especially compared with individuals 73 matched for the genotype of a common T2D risk variant in SLC30A8, p.Arg325. In genome-edited 74 human IPS-derived β-like cells, we establish that the p.Arg138* variant results in reduced SLC30A8 75 expression due to haploinsufficiency. In human β-cells loss of SLC30A8 leads to increased glucose 76 responsiveness and reduced K ATP channel function, which was also seen in isolated islets from 77
Introduction 81
Zinc transporters (ZnTs) regulate the passage of zinc across biological membranes out of the 82 cytosol, while Zrt/Irt-like proteins transport zinc into the cytosol 1 . ZnT8, encoded by SLC30A8, is 83 highly expressed in membranes of insulin granules in pancreatic β-cells, where it transports zinc 84 ions for crystallization and storage of insulin 2 . We have described a loss-of-Function (LoF) variant 85 p.Arg138* (rs200185429, c.412C>T) in the SLC30A8 gene, which conferred 53% protection 86 against T2D
3 . This variant was extremely rare (0.02%) in most European countries but more 87 common (>0.2%) in Western Finland 3 . We also reported a protective frameshift variant 88 p.Lys34Serfs*50 conferring 83% protection against T2D in Iceland. A recent (>44K) exome 89 sequencing study reported >30 alleles in SLC30A8 reducing the risk of T2D, confirming it as a 90 robust target for T2D protection 4 . Further, the SLC30A8 gene also harbors a common variant 91 (rs13266634, c.973T>A) p.Trp325Arg in the C-terminal domain 5 . While the major p.Arg325 allele 92 (>70% of the population) confers increased risk for T2D, the minor p.Trp325 allele is protective 6 . 93
The mechanisms by which reduced activity of ZnT8 protect against T2D are largely unknown. 94
Several attempts have been made to study loss of Slc30a8 function in rodent models, but the results 95 have been inconclusive: knock-out of Slc30a8 led to either glucose intolerance or had no effect in 96 mice 7, 8, 9 , while over-expression improved glucose tolerance without effect on insulin secretion 10 . In 97 a mouse model harbouring the equivalent of the human p.Arg138* variant we were unable to detect 98 any ZnT8 protein and observed no effect on glucose 11 . These rodent in vitro and in vivo experiments 99 present a complex picture which might not recapitulate the T2D protective effects by SLC30A8 LoF 100 mutations in humans. We therefore performed detailed metabolic studies in human carriers of the 101 LoF variant (p.Arg138*) recruited on the basis of their genotype, performed comprehensive 102 functional studies in human β-cell models and compared with the mouse model carrying the human 103 p.Arg138*-SLC30A8 mutation. 104
105
Supplementary Tables 4). Of note, the p.Arg138* carriers had significantly lower proinsulin/C-130 peptide (20 min: P=0.041; 40 min: P=0.043) and proinsulin/insulin (20 min: P=0.006) ratios during 131 test meal suggesting effects on proinsulin conversion . No differences were seen in 132 glucagon, GLP-1 or free fatty acids concentrations during test meal ( Supplementary Fig. 2c-e) . 133
Neither model-based insulin clearance index nor the ratio of insulin and C-peptide areas under the 134 curve during test meal differed between p.Arg138* and p.Arg138Arg, making changes in insulin 135 clearance 13 unlikely ( Supplementary Fig. 2f-g ). 136
Comparison of p.Arg138* vs. p.Arg138Arg-p.Arg325: The above differences were magnified when 137 we restricted the p.Arg138Arg group to carriers of the common risk variant p.Arg325 (middle panel 138 Table 4 ). In patients with 152 newly diagnosed T2D, the p.Trp325Trp carriers showed a trend (P=0.12) to enhanced β-cell 153 sensitivity to glucose during the OGTT ( Supplementary Fig. 3c) . 154
Taken together, all the human in vivo results show that T2D protection by the LoF variant 155 p.Arg138* is due to enhanced glucose-stimulated insulin secretion combined with enhanced 156 proinsulin conversion. The common T2D protective allele p.Trp325 shows a similar -albeit weaker 157 -metabolic phenotype suggesting it might also reduce ZnT8 function. 158
SLC30A8 p.Arg138* variant in human iPSCs 159
The majority of nonsense SLC30A8 alleles (including p.Arg138*) protecting against T2D are 160 located in the first four exons of the eight-exon canonical islet SLC30A8 transcript 161 ENST00000456015 and are predicted to undergo nonsense mediated decay (NMD), a cell 162 surveillance pathway which reduces errors in gene expression by eliminating mRNA transcripts that 163 contain premature stop codons. To confirm that the p.Arg138* allele indeed leads to 164 haploinsufficiency through NMD, we used CRISPR-Cas9 to introduce the p.Arg138* variant into 165 the SLC30A8 locus of the SB Ad3.1 human iPSC cell line ( Supplementary Fig. 4a , Methods). Two 166 hiPSC lines for the p.Arg138*-SLC30A8 variant (Clone B1 and A3) were generated and compared 167 to an unedited p.Arg138Arg-SLC30A8 CRISPR hiPSC line. Both B1 and A3 clones were 168 heterozygous with mono-allelic sequencing confirming the p.Arg138* variant in only one allele 169 ( Supplementary Fig. 4b ). All hiPSC lines passed quality control checks including karyotyping and 170 pluripotency ( Supplementary Fig. 4c ). 171 Accordingly, we subjected our SLC30A8-edited iPSCs to a previously published in vitro endocrine 172 pancreas differentiation protocol 14 ( Supplementary Fig. 4d -k, Methods). At the end of the seven 173 stage protocol, SLC30A8 expression was significantly reduced in cells heterozygous for the 174 p.Arg138* allele (clone B1 0.09±0.04; clone A3 0.08±0.05) compared to unedited control cells 175 (1.03±0.11) (Fig. 4a) . Of note, p.Arg138* allele specific SLC30A8 expression was reduced 176 compared to the WT allele 15 (clone B1: 22.9±2.1%; clone A3: 26.0±3.9%) (Fig. 4b-c) . Inhibition of 177 NMD by cyclohexamide increased expression of the p.Arg138* transcript more than the 178 p.Arg138Arg transcript compared to DMSO control (clone B1:209±52% and clone A3: 199±67% 179 vs. clone B1: 161±30% and clone A3: 132±35%, respectively, Fig. 4d-e) . Taken together, these data 180
show that the protective p.Arg138*-SLC30A8 allele undergoes NMD, resulting in 181 haploinsufficiency for SLC30A8. 182
Impact of SLC30A8 loss in a human β-cell line 183
Since human in vivo studies provided strong evidence for a role of the p.Arg138* on insulin 184 secretion and proinsulin processing, we studied the impact of SLC30A8 loss using siRNA mediated 185 knock down (KD) on both phenotypes in a well characterized human β-cell model EndoC-bH1 16 186 (Methods). By siRNA, we achieved 55-65% decrease in SLC30A8 mRNA (p=0.008) and protein 187 (p=0.016, Fig. 5a-c) . 188 KD of SLC30A8 had no significant effect on glucose-or tolbutamide-stimulated insulin secretion or 189 on insulin content (Fig. 5d -e) but basal insulin secretion was higher in siSLC30A8 transfected cells 190 compared to scrambled siRNA cells (p=0.012, Fig. 5d ), and the inhibitory effect of diazoxide, a 191 K ATP channel opener, on glucose-stimulated insulin secretion was reduced (p=2´10 -3 , Fig. 5d ). We 192 measured the resting membrane conductance (G m ), which principally reflects K ATP channel activity. 193
In control cells, G m was in agreement with that previously reported 17 . SLC30A8 KD reduced G m by 194 65% (p=0.002, Fig. 5f ) without effect on cell size (Fig. 5g) , an effect that correlated with reduced 195 expression of the two genes encoding the K ATP channel subunits SUR1 (ABCC8) and Kir6.2 196 (KCNJ11) (Fig. 5h) Fig. 5i ). The proinsulin-insulin ratios (both total 199 and secreted hormones) were decreased in siSLC30A8 cells (p<0.001, Fig. 5j-k) . Although mRNA 200 of the proinsulin processing genes PC1/3 and CPE was decreased, we could not detect a similar 201 reduction at the protein level (Fig. 5l-n , respectively) encoding an ER 206 adapter protein influencing intracellular calcium levels. Also, expression of genes associated with 207 β-cell maturation and secretion was influenced by SLC30A8 KD with decreased expression of 208 NKX6.1 and PDX1 and increased expression of SOX4, SOX6 and SOX11 (Fig. 5o-p) . 209
In addition, we also observed increased AKT phosphorylation (pAKT-473) and improved cell 210 survival under ER stress (p<0.017, Fig. 5q-s) , mechanisms which also could contribute to the 211 overall protection by preserving β-cell mass 19 . Taken together, these data generated by disrupting 212 SLC30A8 in a human β-cell pointed at multiple mechanisms including changes in proinsulin 213 conversion, K ATP channel activity and cell viability. 214
Metabolic phenotype of mice carrying the human SLC30A8 p.Arg138* 215
Since neither global nor tissue specific Slc30a8 KD mouse models have recapitulated the human 216 phenotype in carriers of the SLC30A8 p.Arg138* variant, we tried to overcome this problem by 217 using a mouse model carrying the Slc30a8 p.Arg138* variant 11 . These mice do not express the 218 truncated ZnT8 protein 11 . On a standard chow diet there was no evidence for enhanced insulin 219 secretion 11 . However, we examined whether they might do so on a high fat diet (HFD). This was 220 indeed the case (Fig. 6a-h) , and the same differences in proinsulin/insulin and proinsulin/C-peptide 221 ratios were seen as in humans. No changes were seen in insulin clearance. 222
Impact of p.Arg138* on protein localization and cytosolic zinc distribution in INS-1 cells 223
Although we found no evidence in either mouse or our human β-cell model to support the presence 224 of a truncated protein we explored the possibility of what might happen if a truncated protein 225 resulted from mRNA evading NMD. Transient overexpression of tagged ZnT8-p.Arg138* fusion 226 proteins in a rat insulinoma cell line, INS-1e, showed distinct punctate distribution patterns, 227 consistent with localization of the truncated ZnT8 protein to secretory granules, as previously 228 observed with the full length protein 20 ( Supplementary Fig. 5a -c) Additionally, Western blot 229 showed stable expression of truncated ZnT8 in native INS1e cells ( Supplementary Fig. 5d) Supplementary Fig. 5e-h) . 234
Influence of common SLC30A8 variants p.Trp325Arg in primary human islets 235
While adult human islets show high levels of SLC30A8 expression there was no reproducible effect 236 of the p.Arg325Trp variant on SLC30A8 expression in human islets from cadaveric donors (Fig.  237   7a) . Islets obtained from cadaveric p.Trp325 carriers secreted more insulin than p.Arg325Arg 238 carriers (Fig. 7b-e) . The increased glucose responsiveness was observed at submaximal glucose 239 stimulation (6 mM) rather than at maximal glucose stimulation (16.7 mM) (Fig. 7b-c) . Increasing 240 glucose from 1 mM to 6 mM stimulated insulin secretion 2.2-and 2.7-fold in p.Arg325 and 241 p.Trp325 carriers respectively, with no effect on insulin content (Fig. 7c-d ). This secretion pattern 242 echoes the one observed after siRNA of SLC30A8 KD in EndoC-bH1. Insulin secretion in p.Trp325 243 carriers was also increased at high glucose (16.7 mM) when co-exposed to depolarizing [K + ] o (70 244 mM) (Fig. 7e) as also seen after SLC30A8 KD in EndoC-bH1. 245
As SLC30A8 is highly expressed in human alpha cells 1 , we also measured glucagon secretion from 246 the same islets (Fig. 7f) . In islets from p.Arg325Arg donors, 6 mM glucose inhibited glucagon 247 secretion by ~50% compared to 1 mM glucose. In islets from p.Trp325Arg donors, glucagon 248 secretion at 1 mM glucose was reduced by 50% compared to p.Arg325Arg donors with no effect on 249 glucagon content (Fig. 7f-g ). 250
We also explored whether the p.Trp325Arg variant would have trans-eQTL effects on genes 251 involved in insulin production and secretion 22 (Fig. 7a) . Expression of PCSK1 (P=0.041) 252
and PCSK2 (P=0.045) were reduced. Among the genes encoding for K ATP channels subunits 253 only ABCC8 (P=0.049) expression was significantly affected in islets from p.Trp325 carriers 254 compared to non-carriers (Fig. 7a) . Taken together, the data suggest the common T2D-protective 255 allele (p.Trp325) may improve the response to a glucose challenge by enhancing insulin secretion 256 and possibly by reducing glucagon secretion in primary human islets. 257
Discussion 258
The current study demonstrates the strengths of using human models for studying the consequences 259 of LoF mutations in humans, particularly by demonstrating a stronger protective effect of 260 p.Arg138* in individuals carrying the common risk p.Arg325 allele on the same haplotype. 261
However, the minor p.Trp325 allele was also associated with protection against T2D albeit less 262
pronounced. This emphasizes the importance of taking into account the genetic background of the 263 human LoF carrier. 264
Whilst the data from all our sub-studies are consistent with increased glucose responsiveness, the 265 precise molecular mechanisms for these phenotypes, involvement of zinc and an explanation for 266 why there are discrepancies between humans and rodents remain elusive. In the IPS-derived beta-267 like cells, the p.Arg138* variant dramatically lowered expression with evidence of NMD resulting 268 in haploinsufficiency. Similarly, in the mouse model we were unable to detect the truncated 269 protein, but we could detect appreciable levels of RNA 11 . 270
The most reproducible finding in all sub-studies of p.Arg138* was enhanced glucose-stimulated 271 insulin secretion accompanied by increased conversion of proinsulin to C-peptide and insulin. 272
Carriers of p.Trp325 displayed a similar phenotype, which is in line with a previous study showing 273 impaired proinsulin conversion in carriers of the risk p.Arg325 allele 23 . There could also be other 274 potential explanations for this effect, as it has been suggested that it takes some time for insulin to 275 mature and become biologically active 24, 25 Taken together, our data consistently demonstrate that heterozygosity for a LoF mutation 291 p.Arg138* and homozygosity for a common variant p.Trp325Trp of the SLC30A8 are associated 292 with increased insulin secretion capacity and lower risk of T2D without any negative effect. 32 . In the current study, we 307 included >14,000 individuals (Botnia family study=5678, PPP=4862, and DIREVA=3835). All 308 participants gave their written informed consent and the study protocol was approved by the Ethics 309
Committee of Helsinki University Hospital, Finland (the Botnia studies) and the Ethics Committee 310 of Turku University Hospital (DIREVA). 311
Oral Glucose Tolerance Test (OGTT) and test meal: Subjects maintained a weight-maintaining 312 diet and avoided vigorous exercise for 3 days prior to the OGTT or test meal, which were 313 performed after an overnight fast. Height, weight, hip and waist circumferences, fat percentage (%, 314 bioimpedance analyzer) and blood pressure (sitting, 3 measurements after 5 min rest) were 315 measured. The participants ingested 75 g dextrose (in a couple of minutes, OGTT) or a 526 kcal 316 mixed meal (in 10 minutes, test-meal: 76 g carbohydrate, 17 g protein and 15 g fat). Blood samples 317
were drawn from an antecubital vein for plasma (P-) glucose and serum (S-) insulin and C-peptide 318 at 0, 30, 120 min during the OGTT; for P-glucose, P-glucagon, S-insulin, S-C-peptide, S-zinc, and 319 concentration at the beginning of the study 35 . MRT(ins) is the mean residence time of insulin, and 361 was assumed to be 27 minutes as reported previously 36 . 362
Genotyping: We analyzed genotype data for rs13266634 (p.Trp325Arg) and rs200185429 363 (p.Arg138*) for three cohorts genotyped with different genome-/exome-wide chips: the Botnia 364 family cohort (Illumina Global Screening array-24v1, genotyped at Regeneron Pharmaceuticals), 365 PPP-Botnia (Illumina HumanExome v1.1 array, genotyped at Broad Institute 3 ) and DIREVA 366 (Illumina Human CoreExome array-24v1, genotyped at LUDC). For the Botnia family cohort, 367 genotype data for p.Arg138* were imputed (info score >0.95) from the available GWAS data by 368 phasing using SHAPT-IT v2 37 and imputing using the GoT2D reference panel 38 by IMPUTEv2 39 . 369
The carrier status of imputed p.Arg138* was additionally confirmed from exome sequencing data. 370
Genotyping (p.Trp325Arg and p.Arg138*) the family members participating in the genotype based 371 recall study (test meal study) was performed using TaqMan (Applied Biosystems, Carlsbad, CA). 372
The genotype distribution of both variants was in accordance with Hardy-Weinberg equilibrium in 373 all the cohorts. We did not detect any Mendelian errors in the families. 374 Genetic Association Analysis: All the quantitative traits were inversely normally transformed 375 before the analyses. The family-based recall study included only non-diabetic subjects during test 376 meal and analysis of data was performed using family-based association analyses adjusting for age, 377 sex, BMI, and other covariates if appropriate, using QTDT (v2.6.1) 40 . The significance levels were 378 derived from 100,000 permutations as implemented in QTDT. Also, the OGTT study included only 379 non-diabetic subjects. The association analysis was performed using mixed linear model 380 considering genetic relatedness among samples as implemented in GCTA (v1.91) 41 . 381
Study participants and their clinical measurements in Verona Newly Diagnosed Diabetes Study 382 (VNDS): The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS; NCT01526720) is an 383
ongoing study aiming at building a biobank of patients with newly diagnosed (within the last six 384 months) type 2 diabetes. Patients are drug-naïve or, if already treated with antidiabetic drugs, 385 undergo a treatment washout of at least one week before metabolic tests are performed 42 . Each 386 subject gave informed written consent before participating in the research, which was approved by 387 the Human Investigation Committee of the Verona City Hospital. Metabolic tests were carried out 388 on two separate days in random order 42 . Plasma glucose concentration was measured in duplicate 389 with a Beckman Glucose Analyzer II (Beckman Instruments, Fullerton, CA, USA) or an YSI 2300 390
Stat Plus Glucose&Lactate Analyzer (YSI Inc., Yellow Springs, OH, USA) at bedside. Serum C-391 peptide and insulin concentrations were measured by chemiluminescence as previously described 42 . 392
The analysis of the glucose and C-peptide curves during the OGTT was carried out with a 393 mathematical model as described previously 42 . This model was implemented in the SAAM 1.2 394 software (SAAM Institute, Seattle, WA) to estimate its unknown parameters. Numerical values of 395 the unknown parameters were estimated by using nonlinear least squares. Weights were chosen 396 optimally, i.e., equal to the inverse of the variance of the measurement errors, which were assumed 397 to be additive, uncorrelated, with zero mean, and a coefficient of variation (CV) of 6-8%, A good fit 398 of the model to data was obtained in all cases and unknown parameters were estimated with good 399 precision. In this paper we report the response of the beta cell to glucose concentration 400 Several guide RNAs (gRNAs) were designed using MIT CRISPR tool (http://crispr.mit.edu/) to 422 target near exon 3 of SLC30A8 (ENST00000456015). The gRNAs were also subjected to an 423 additional BlastN search (www.ensembl.org) to confirm specificity and identified no additional off-424 target sites. The gRNA (AGCAGGTACGGTTCATAGAG) was sub-cloned into the BsbI restriction 425 sites in pX330 44 plasmid that was previously modified to contain a puromycin selection cassette. 426
Single strand oligonucleotides for homology-directed repair (HDR) were synthesised by 427
Eurogentec, stabilised by addition of a phosphorothioate linkage at the 5' end, and contained two 428 nucleotide changes: i) the T2D-protective nonsense mutation at codon-138 (c.412C>T, p.Arg138*), 429 which also mutated the PAM sequence, and ii) a silent missense mutation at codon-139 (c.
Human iPSCs were co-transfected with SLC30A8-px330-puromycin resistant vectors and HDR 432 oligos using Fugene6 according to manufacturer's guidelines (Promega #E2691). Following 433 transient puromycin-selection, single clones were picked and expanded as described previously 45 . 434
Genotyping PCR was performed using primers (Forward: TACCCCAGGAATGGCTTCTC; 
Quantification of SLC30A8 gene expression in Beta-like Cells derived from CRISPR-edited 482
hiPSCs: Expression of SLC30A8 was measured at the end of stage 7 using quantitative PCR 483 (qPCR). Briefly, RNA was extracted using TRIzol Reagent (Life Technologies #15596026) 484 according to manufacturer's instructions. cDNA was amplified using the GoScript Reverse 485
Transcription Kit (Promega #A5000). qPCR was performed using 40 ng of cDNA, TaqMan® Gene 486 Expression Master Mix (Applied Biosystems #4369017) and primer/probes for SLC30A8 487 (Hs00545182_m1) or the housekeeping gene TBP (Hs00427620_m1). Gene expression was 488 determined using the DDCT method by first normalizing to TBP and then to the control 489 p.Arg138Arg sample (n=6-7 wells from two differentiations). 490
Allele-specific SLC30A8 expression in Beta-like Cells derived from CRISPR-edited hiPSCs: 491
Stage 7 cells were treated with 100 μg/mL cycloheximide (Sigma #C4859) or DMSO (Sigma 492 #D2650) for four hours at 37 o C 47 before harvesting for RNA and cDNA synthesis as above. Allele 493 specific expression was measured using the QX10 Droplet Digital PCR System and C1000 Touch 494 Thermal Cycler according to manufacturer's guidelines (Bio-Rad). Custom primers and probes for 495 the detection of p.Arg138* variant were designed using Primer3Plus (Applied Biosystems): 496 Forward primer AGTCTCTTCTCCCTGTGGTT; Reverse primer 497 ATGATCATCACAGTCGCCTG; FAM probe 5'-FAM-ATGGCACCGAGCTGA-MGB-3'; VIC 498 probe 5'-VIC-ATGGCACTGAGCTGAGA-MGB-3'. Results were analysed using Quanta Soft 499 software (Bio-Rad) and presented as a ratio of wildtype to HDR-edited allele expression (n>3 wells 500 from two differentiations). 501
EndoC-bH1 culture 502
The results obtained in EndoC-bH1 are from two distinct teams (Helsinki and Oxford) with 503 different batches of EndoC-bH1 cultures. Here, we report both methods and specify for each 504 experiment the origin of the culture (Helsinki or Oxford). EndoC-βH1 cells were cultured in 505 medium and grown on a matrix as described previously 48 and tested negative for mycoplasma. 506 
S., 532
France) for the measurement of total insulin content. Secreted and intracellular insulin were 533 measured using a commercial human insulin Elisa kit (Mercodia AB, Uppsala, Sweden) as per 534
manufacturer's instructions (Helsinki). 535

Electrophysiological measurements in EndoC-βH1 cells (Oxford): SLC30A8 was knocked down 536
in EndoC-βH1 as above. K + ATP channel conductance was measured in a perforated patch whole cell 537 configuration, and patch-clamped using an EPC 10 amplifier and HEKA pulse software. KREBS 538 extracellular solution was perfused in at 32 o C and contained: 138 mM NaCl, 3.6 mM KCl, 0.5 mM 539
MgSO 4 , 10 mM HEPES, 0.5 mM NaH 2 PO 4 , 5 mM NaHCO 3 , 1.5 mM CaCl 2 , 1 mM glucose and 100 540 μM Diazoxide (Sigma-Aldrich #D9035). The perforation of the membrane was achieved using an 541 intra-pipette solution containing: 0.24 mg/mL amphotericin B, 128 mM K-gluconate (Sigma 542 #Y0000005 and G4500 respectively), 10 mM KCl, 10 mM NaCl, 1 mM MgCl 2 , 10 mM HEPES, 543 The purple formazan crystals generated after 2 h incubation with MTT buffer were dissolved in 571 DMSO, and the absorbance was recorded on a microplate reader at a wavelength of 540nm. 572 RNA (mRNAs) sequencing of EndoC-βH1 cells: For RNA sequencing post 96h siScramble 573 (n=3) or siSLC30A8 (n=3) transfected EndoC-βH1 cells were used and the total RNA was 574 extracted with Macherey-Nagel RNA isolation kit as per manufacturer's instruction. RNA 575 sequencing was performed using Illumina TruSeq-mRNA library on NextSeq 500 system (Illumina) 576
with an average of >15 million paired-end reads (2 × 75 base pairs). RNA sequencing reads were 577 aligned to hg38 using STAR (Spliced Transcripts Alignment to Reference) 51 , genome annotations 578 were obtained from the GENCODE (Encyclopedia of Genes and Gene Variants) v22 52 program, and 579 reads counting were done using featureCounts 53 . Further downstream analysis was perform using 580 edgR 54 software package, low expressed (<1 average count per million) genes were removed, read 581 counts were normalized using TMM 55 (trimmed mean of M-values), differential expression analysis 582 was performed using method similar to Fisher's Exact Test and corrected for multiple testing using 583
FDR (1%). 584
Data Analyses: Data are reported as mean (SEM). Statistical analyses were performed using Prism 585 6.0 (GraphPad Software). All parameters were analyzed using Mann-Whitney test or Unpaired 586
Student's t-test as indicated. 587
Mouse Model 588
Animals: All procedures were conducted in compliance with protocols approved by the Regeneron 589 Pharmaceuticals Institutional Animal Care and Use Committee. The Slc30a8
Tgp.Arg138* mouse line is 590 made in pure C57Bl/6 background by changing nucleotide 409 from T into C in exon 3, which 591 changes the arginine into a stop codon 11 . The mutated allele has a self-deleting neomycin selection 592 cassette flanked by loxP sites inserted at intron 3, deleting 29 bp of endogenous intron 3 sequence. All methods and protocols using human pancreatic islets were performed in accordance with the 679 relevant guidelines and regulations in the UK (Human Tissue Authority, HTA). Expression data for 680 SLC30A8 estimated by RNA sequencing as described previously 57 . For in vitro insulin secretion, 681 islets were pre-incubated in Krebs-Ringer buffer (KRB) containing 2 mg/mL BSA and 1 mM 682 glucose for 1 hour at 37°C, followed by 1-hour stimulation in KRB supplemented with 6mM 683 glucose. Insulin content of the supernatant was determined by radioimmunoassay (Millipore UK 684
Ltd, Livingstone, UK) as described previously 58 . 685
Human pancreatic islets from LUDC: Human pancreatic islets were obtained from the Human 686
Tissue Laboratory (Lund University, www.exodiab.se/home) in collaboration with The Nordic 687
Network for Clinical Islet Transplantation Program (www.nordicislets.org) 59, 60 . All the islet donors 688 provided their consent for donation of organs for medical research and the procedures were 689 approved by the ethics committee at Lund University (Malmö, Sweden, permit number 2011263). 690
Islet preparation for cadaver donors, their purity check and counting procedure have been described 691 previously 61 . Static in vitro insulin secretion assay from 91 islets (non-diabetic individuals) was 692 performed as described previously 61, 62 . Briefly , six batches of 12 islets per donor were incubated for 693 1 hour at 37°C in Krebs Ringer bicarbonate (KRB) buffer in presence of 1 mM or 16.7 mM 694 glucose, as well as 1 mM or 16.7 mM glucose together with 70 mM KCl. Insulin concentrations in 695 the extracts was measured using a radioimmunoassay kit (Euro-Diagnostica, Malmö, Sweden). The 696 Association of p.Trp325Arg genotype with expression of SLC30A8 and other genes involved in 697 insulin production and processing 22 was performed using RNA sequencing from islets of 140 non-698 diabetic individuals as described previously 59, 60 . Briefly, RNA sequencing of islets was done using 699 a HiSeq 2000 system (Illumina) for an average depth of 32.4 million paired-end reads (2 × 100 base 700 pairs) 59, 60 . RNA sequencing reads were aligned to hg19 using STAR (Spliced Transcripts 701 Alignment to Reference) 51 . Genome annotations were obtained from the GENCODE (Encyclopedia 702 of Genes and Gene Variants) v20 52 program and read counting was done using featureCounts 53 . 703
Read counts were normalized to total reads (counts per million) and additionally across-samples 704 normalization was done using TMM method 55 . Association analysis (so called eQTL) was 705 performed on inverse normalized expression values using linear regression adjusted for age, sex and 706 islets purity. 707
Statistics 708
Detail information regarding statistical tests used for each sub-study has been provided in their 709 respective method section or with figure legends. 710
Data availability 711
The data that support the findings of this study are available from the corresponding author on 712 
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